Reminder:
Alliance on track to achieve its 2020 mission indicators

<table>
<thead>
<tr>
<th>Category</th>
<th>2015 Baseline</th>
<th>2020 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Under-5 Mortality</strong></td>
<td>62 per 1,000</td>
<td>57 per 1,000</td>
</tr>
<tr>
<td><strong>Children Immunised (with Gavi support)</strong></td>
<td>127 million</td>
<td>300 million</td>
</tr>
<tr>
<td><strong>Future Deaths Averted</strong></td>
<td>2.5 million</td>
<td>5-6 million</td>
</tr>
<tr>
<td><strong>Future DALYS Averted</strong></td>
<td>105 million</td>
<td>250 million</td>
</tr>
<tr>
<td><strong>Vaccines Sustained (after Gavi support ends)</strong></td>
<td>N/A</td>
<td>100%</td>
</tr>
</tbody>
</table>
Empirical evidence showing wider impact of immunisation

**Gender**
Measles vaccination **benefits girls more**

**Poverty**
30-40% of deaths averted by PCV / pneumonia treatment occur in the **poorest wealth quintile** (Ethiopia study)

**Malnutrition**
Immunisation **reduces** the proportion of children with stunting by 27% (Kenya study)

**Education**
One additional grade of schooling **achieved for every 6 children** vaccinated in poor, rural settings (South Africa study)
More countries are embracing survey results

New coverage estimates (WUENIC) to be available in July

SG1: Accelerate vaccines

More countries are embracing survey results
Continued progress on routine introductions and uptake

**Alliance KPI on post-introduction target achieved**

<table>
<thead>
<tr>
<th>% of target countries that have introduced Gavi-supported vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gavi 1.0</strong></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>HPV</td>
</tr>
<tr>
<td>Measles (2nd Dose)</td>
</tr>
<tr>
<td>PCV</td>
</tr>
</tbody>
</table>

**Note:** Introductions in 68 Gavi-eligible countries (except for regional vaccines – Yellow Fever, Japanese Encephalitis and Meningitis A where target countries are a subset of eligible countries) – introductions exclude certain product switches during Gavi 1.0 and 2.0 period.
Campaigns are a substantial part of Gavi efforts

Number of routine introductions vs campaigns 2016-2019* (forecast)

- **Routine introductions:** 96
- **Follow-up campaigns:** 38
- **Catch-up campaigns:** 31

### Madagascar

**McV1 routine coverage (WUENIC %)**

- **2007:** 81
- **2017:** 58

- **Measles outbreak Sept. 2018 - May 2019:** >145,000 cases and >900 deaths
- **Regular campaigns** did not prevent outbreak

*Note: excluding HPV demo & Multi Age Cohort campaigns*
A closer look at Pakistan’s recent measles campaign

SG1: Accelerate vaccines

- Over 37 million children vaccinated, 10% zero-dose
- 93% coverage across provinces
- 0.63% refusal
- No serious adverse events
- Stepped up advocacy, communication & social mobilisation
- Detailed data-driven microplanning
- Strong collaboration with polio eradication staff
- PEF TCA: US$ 3m to core partners for 27 on-ground staff
Positive trends being seen in new surveys on gender and wealth equity

- 6 out of 8 countries show a reduction of coverage inequities among non-educated mothers
- 5 show a reduction across income groups

“Vaccination is the most equitably distributed health service across wealth quintiles”
India’s Self Employed Women Association (SEWA) with 1.5m membership pledging their support to immunisation
SG2: Strengthen systems

New data for three indicators to be available in July
Effective Vaccine Management (EVM) scores are improving

- Since 2016, **23 countries** have had new EVM assessments
- **18 countries** have shown significant improvement (+11 pp on average)
EVM improvements in areas where Gavi has invested

Average EVM scores per criteria from previous & latest assessments

- E1. Arrival procedures
- E2. Temp. monitoring
- E5. Maintenance
- E6. Stock mgmt
- E7. Distribution
- E8. Vaccine mgmt
- E9. Info mgmt & supp. Functions

~47%  ~19%  ~22%

~88% of Gavi’s supply chain investments are in areas with biggest EVM improvements

% of Gavi’s supply chain investments
SG3: Improve sustainability

New data for three indicators to be available in July
Gavi’s model driving higher allocation of domestic resources for immunisation

Countries’ co-financing & self-financing in US$ millions

Proportion of country co-financing & self-financing to Gavi supported routine programmes

<table>
<thead>
<tr>
<th>Year</th>
<th>Self-financing (India - provisional)</th>
<th>Self-financing est.</th>
<th>Co-financing</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>116</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>125</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>238</td>
<td>83</td>
<td>135</td>
</tr>
<tr>
<td>2017</td>
<td>296</td>
<td>112</td>
<td>48</td>
</tr>
<tr>
<td>2018</td>
<td>430</td>
<td>63</td>
<td>129</td>
</tr>
</tbody>
</table>

SG3: Improve sustainability
Ripple effect beyond Gavi-supported vaccines

Domestic and donor funding for non-Gavi supported vaccines

Note: Gavi-supported countries procuring through UNICEF: funding for non-Gavi supported vaccines (without OPV)
SG4: Market shaping
Progress on price reduction and product innovation; continued risks on supply

**Vaccine Price Reduction**
- Cost of full course of Penta, PCV and Rota vaccines:
  - 2015: $20
  - 2016: $19
  - 2017: $17
  - 2018: $16
  - 2020: N/A

**Supply Security**
- Vaccine markets where supply meets demand:
  - 2015: 7/11
  - 2016: 9/11
  - 2017: 8/11
  - 2018: 8/11
  - 2020: 11

**Healthy Market Dynamics**
- Vaccine markets classified with moderate or high healthy dynamics:
  - 2015: 1
  - 2016: 2
  - 2017: 3
  - 2018: 3
  - 2020: 6/11

**Product Innovation**
- No. vaccines & immunisation products with improved characteristics:
  - 2015: 0
  - 2016: 3
  - 2017: 5
  - 2018: 7
  - 2020: 10
Continued Alliance efforts to mitigate global supply shortage for Rotavirus, HPV and IPV

**HPV**
- Step-up in supply but remains **below Gavi requirements**
- Supply in 2019 & 2020 **lower than expected**

**Rotavirus**
- **Alliance collaboration** to mitigate impact of shortage
- 2 new manufacturers in 2018 and 1 **new presentation** in 2019

**IPV**
- Improvements: supply secured for **routine programmes**
- Supply & pricing **expected to improve** with new entrants